Cover Image
市場調查報告書

女性的低性慾障礙(HSDD):開發平台分析

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 268986
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
女性的低性慾障礙(HSDD):開發平台分析 Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015
出版日期: 2015年07月22日 內容資訊: 英文 51 Pages
簡介

所謂低性慾障礙(HSDD)是指對性行為的興趣和慾望缺乏·不足的狀態。發病的要素有神經不安症,憂鬱症,雄激素缺乏症,及慢性腎衰竭和高催乳激素血症等慢性消耗性疾病等。治療方法有抗憂鬱症藥及荷爾蒙療法。

本報告提供女性的低性慾障礙(HSDD)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

女性的低性慾障礙(HSDD)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

企業開發中的產品

治療藥的開發企業

  • Apricus Biosciences, Inc.
  • Emotional Brain BV
  • Palatin Technologies, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (bupropion hydrochloride + trazodone hydrochloride)
  • (sildenafil citrate + testosterone)
  • alprostadil
  • bremelanotide
  • flibanserin

最新開發平台趨勢

暫停中的計劃

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6910IDB

Summary

Global Markets Direct's, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015', provides an overview of the Female Hypoactive Sexual Desire Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Female Hypoactive Sexual Desire Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview
    • Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis
  • Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies
  • Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Female Hypoactive Sexual Desire Disorder - Products under Development by Companies
  • Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
    • Apricus Biosciences, Inc.
    • Emotional Brain BV
    • Palatin Technologies, Inc.
  • Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupropion hydrochloride + trazodone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (sildenafil citrate + testosterone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bremelanotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • flibanserin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates
  • Female Hypoactive Sexual Desire Disorder - Dormant Projects
  • Female Hypoactive Sexual Desire Disorder - Dormant Projects
  • Female Hypoactive Sexual Desire Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Jun 05, 2015: S1 Biopharma Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
      • Jun 04, 2015: Palatin Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
      • Jun 02, 2015: FDA Advisory Committee to Review Sprout Pharma's HSDD Drug
      • Mar 04, 2015: UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets
      • Feb 17, 2015: Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application For The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women
      • Jan 07, 2015: Sprout Pharmaceuticals To Present At 33rd Annual J.P. Morgan Healthcare Conference
      • Nov 22, 2014: Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment
      • Nov 22, 2014: Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released At Sexual Medicine Society of North America Meeting
      • Feb 11, 2014: Sprout Pharmaceuticals Receives Clear Guidance From FDA On Path Forward To Resubmit New Drug Application For Flibanserin, The First Potential Medical Treatment For Hypoactive Sexual Desire Disorder In Premenopausal Women
      • Dec 11, 2013: Sprout Pharmaceuticals Appeals FDA Decision On New Drug Application For Flibanserin To Treat Hypoactive Sexual Desire Disorder In Premenopausal Women
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2015
  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H2 2015
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H2 2015
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H2 2015
  • Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2015
  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top